tbuckley/cabot-search huggingface dataset:
POS0421 MRI-BASED SYNTHETIC CT IS SUPERIOR TO CONVENTIONAL MRI FOR THE DETECTION OF STRUCTURAL LESIONS IN POSTPARTUM WOMEN AFTER 5 YEAR FOLLOW-UP
Authors: G. Varkas, L. De Meester, M. De Hooge, N. Herregods, L. Jans, P. Carron, F. Van den Bosch, D. Elewaut
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Recently, a novel imaging technique has been introduced to detect structural lesions in sacroiliac joints, addressing the challenges associated with the evaluation of these lesions on routine T1-weighted MRI scans. MRI-based synthetic CT (sCT) allows detection of structural lesions like erosions with CT-like accuracy, all while eliminating the need for CT-related radiation exposure. Previously, we reported on the presence of SpA-like lesions in postpartum women, showing high prevalence of bone marrow edema (BME), while the presence of structural lesions was low in these subjects. <h3>Objectives:</h3> To compare structural lesions identified on routine MRI to lesions identified on sCT in postpartum women, 5 years after given birth. <h3>Methods:</h3> Synthetic CT images were reconstructed with commercially available software (BoneMRI Pelvic Region, version 1.5; MRIguidance). The software reconstructed sCT images from 3D T1-GRE images using a deep learning method based on the U-net architecture [1]. MRI scan protocol contained Short Tau Inversion Recovery and T1-weighted sequences. Both MRI and sCT were available in 18 women. The sCT images were assessed by 2 readers and the MRI by 3 readers. Results are based on the consensus of at least 2 readers, within a modality. Both sCT and MRI were assessed separately for the presence of absence of erosions, fatty lesions and ankylosis per sacroiliac joint quadrant. This resulted in a maximum score of 144 quadrants per structural lesions. Taking into account that ankylosis always occurs in 2 quadrants. Descriptive data were presented on quadrant level. <h3>Results:</h3> Both MRI and sCT were available in 18 women with a mean age of 35.4 years (SD 2.6), all of whom were HLA-B27 negative. Mean BMI was 20.7 kg/m<sup>2</sup> (SD 1.6). Six (33%) of these women reported back pain. On MRI, 1 quadrant with erosions was reported, compared to 5 quadrants with erosions seen on sCT. However, none of these erosions were seen on both modalities. Three quadrants with sclerosis were reported on MRI and sCT, compared to 26 quadrants with sclerosis seen on sCT only. No ankylosis was reported on MRI, nor on sCT. <h3>Conclusion:</h3> Overall, few structural lesions were seen in patients 5 years postpartum both on MRI and on sCT/bone MRI. Nevertheless, when comparing MRI to sCT, sclerosis and -to a lesser extent- erosions were more frequently accounted for in the latter. sCT combines the sensitivity for detection of structural lesions of CT, with the established benefits of MRI, displaying unprecedented opportunities for use in clinical practice. <h3>REFERENCES:</h3> [1] Jans et al. Radiology 2021 Feb;298(2):343-349. [2] Ronneberger O et al. MICCAI 2015. Lecture Notes in Computer Science 2015(9351); 234–241. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1096 COMBINED TESTING OF ANTI-CD74 IgA AND ANTI-UH-axSpA ANTIBODIES INCREASES DIAGNOSTIC POTENTIAL FOR axSpA
Authors: P. Ruytinx, E. Luyten, A. Agten, F. Vandenabeele, K. De Vlam, V. Somers
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA antibodies to 4 Hasselt University (UH)-axSpA antigens (UH-axSpA-IgG 4, 8 and UH-axSpA-IgA 1,10), corresponding to non-physiological peptides and to a novel axSpA autoantigen, Double homeobox protein 4 (DUX4) [1]. Validation of antibody reactivity in plasma samples of axSpA patients from the Leuven spondyloarthritis biologics cohort (BIOSPAR) cohort revealed antibody reactivity against at least one of these 4 peptide targets in 15.9 % of axSpA patients (26/164) [2]. In addition, IgA antibodies against CD74, involved in the assembly of and the prevention of premature peptide-binding to major histocompatibility complex (MHC) class II has been shown in patients with axSpA. <h3>Objectives:</h3> Here we aim to determine the diagnostic potential of the anti-CD74 IgA antibodies in combination with previously determined IgG and IgA antibodies against the 4 UH-axSpA antigens. <h3>Methods:</h3> Anti-CD74 IgA antibodies were measured using the AESKULISA SpA Detect Kit (AESKU Diagnostics, Wendelsheim, Germany) in axSpA patients from the BIOSPAR cohort and patients with chronic low back pain (CLBP) served as the control group. The cut-off of the ELISA was 20 U/ml. <h3>Results:</h3> In the BIOSPAR cohort, anti-CD74 IgA antibodies were present in 29.3% of axSpA patients (48/164) versus no presence in the CLBP patients (0/58) (p&lt;0.0001). Additional testing for the presence of antibodies against the 4 UH-axSpA peptides further increased the antibody reactivity in 40.2% of the patients (66/164) and only in 3.4% of the CLBP patients (2/58) (p&lt;0.0001). Interestingly, we found a significant increase in age (p=0.0142), disease duration (p=0.0184) and Bath Ankylosing Spondylitis Functional Index (BASFI) (p=0.0101) in axSpA patients who tested positive for antibodies against at least one of the 4 UH-axSpA antigens or CD74 compared to seronegative patients. <h3>Conclusion:</h3> Combined testing for anti-CD74 IgA antibodies and the 4 novel anti-UH-axSpA antibodies results in improved diagnosis of axSpA. <h3>REFERENCES:</h3> [1] Quaden D, et al., Arthritis Rheumatol, 2020 [2] Ruytinx P, et al., Front Med (Lausanne), 2022 <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1179 DETECTING EXTRACELLULAR MATRIX TURNOVER IN axSpA PATIENTS WITH CONCOMITANT INFLAMMATION ON MRI AND NORMAL CRP
Authors: F. Gillesberg, R. Østgård, J. H. Mortensen, M. Pehrsson, S. Holm Nielsen, B. Deleuran, A. C. Bay-Jensen, T. W. Kragstrup
Journal: Annals of the Rheumatic Diseases (2024)
POS0127-PARE LISTEN TO YOUR BODY – A CAMPAIGN ABOUT OSTEOARTHRITIS ON NATIONAL TV AND SoMe
Authors: L. M. Thomsen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Arthritis is the most common disease in Denmark, with 700,000 persons already diagnosed; experts estimate that just as many live with the condition without knowing it. The first step in solving the burden of rheumatic diseases, including osteoarthritis, is acknowledging that there is a problem for the individual and for the society. Most people recognize the insight that we groan more as we get older, but they do not want to admit that they have osteoarthritis. So we gently nudge them in this campaign, in order tell them, that our bodies are trying to tell us something. The Campaign was launched on national TV and social media during 4 weeks in autumn 2023 and will be repeated in spring 2024. <h3>Objectives:</h3> The purpose with the campaign is: 1)To increase the awareness about arthritis (primarily osteoarthritis) in general public, and 2)To increase the support to the Danish Rheumatism Association. <h3>Methods:</h3> The campaign uses humor to depict the agony of creaking joints. A "Pain Choir" was filmed at the Royal Danish Music Conservatory in Copenhagen, gathering musicians and arthritis "suffers" for a festival of creaking joints. The campaign consist of: One centerpiece film with the "Pain Choir", four short film with personal stories about living with osteoarthritis; two of them are celebrities in Denmark. All films lead to a webpage, where you can order a free e-package with information, exercises and research news about OA. A beneficial membership and other types of support to the association are marketed too. The films and material is to be shown digitally at the congress. <h3>Results:</h3> The campaign will be systematically evaluated on short and long terms outcomes e.g. visitors to the webpage, e-packages ordered, support given to the association etc. The evaluation will be completed in May and presented at the congress. At the first launch of the campaign last autumn, the centerpiece film were seen by 1.300.000 persons in a period of 4 weeks and won European awards within marketing and healthcare. <h3>Conclusion:</h3> The Danish Rheumatism Association has launched a new digital campaign on TV and Social Media, in order to increase the awareness to osteoarthritis and the support to the Association. The campaign consist of films shown on national TV and Social Media: One centerpiece film using humor and music in relation to creaking joints and four films with personal stories. All films leads to a webpage, where an e-guide about arthritis is offered freely and support to the association are marketed. The Campaign is going to be evaluated on short and long terms outcomes this spring, and the results represented on the congress. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0108 EVALUATION OF ORAL BISPHOSPHONATE THERAPY COMPLIANCE
Authors: S. Bousselham, K. Nassar, S. Zaher, A. Ajerouassi, S. Janani
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Osteoporosis is the most frequent bone fragility disease with High risk of fractures by a decrease of bone strength. There is wide range of osteoporosis treatments. Oral bisphosphonates (BP) have been used for years with a good profile of effectiveness and tolerance, but present the main challenge, like the problem of therapeutic compliance. <h3>Objectives:</h3> Assess the degree of compliance of osteoporotic patients on oral BPs with respect to their treatment in order to improve therapeutic adherence. <h3>Methods:</h3> This is a uni-centric descriptive and comparative cross-sectional study conducted in the rheumatology department of the University Hospital in Casablanca among 3 years, from August 2020 to March 2023. The inclusion criteria was any patient followed up in the rheumatology department, at the bone disesas unit, for osteoporosis and treated with oral BP. The exclusion criteria was osteoporotic patients treated with the intravenous bisphosphonate or with other antiosteoporotic medications. <h3>Results:</h3> Were identified 374 patients (368 women and 6 men). sex ratio F/M = 61.3. The mean age was 65.8 years. 66% of patients were treated with alendronic acid (n=247), 12% with ibandronic acid (n=45), and 22% with risedronic acid (n=82). The average length of follow-up was 4.8 years (6 months and 13 years). 85.5% of patients (n=319) took their BP regularly, 14.5% had bad compliance (n=55), 12% were on weekly BP (n=46) and 2.5% on monthly BP (n=9). This was explained by a lack of resources in 9% of cases (n=34): 5% of them were on alendronic acid (n=19), 3% were on risedronic acid (n=11) and 1% were on ibandronic acid (n=4), a lack of understanding in 3. 5% of cases (n=13) who were all on alendronic acid (n=5) or risedronic acid (n=8), product unavailability or side effects in 1% of cases each (n=4) who were on alendronic acid. The side effect described in the cases treated with alendronic acid was digestive discomfort (epigastralgia, nausea) (n=4) <h3>Conclusion:</h3> Adherence to osteoporosis treatment can be poor, because the benefits of osteoporosis treatments are not immediately apparent to patients. According to our study, adherence to oral BP taken monthly was higher than those taken weekly. Adherence to monthly oral BP was satisfactory and superior to weekly oral BP in our study. However, compliance remains suboptimal, and greater attention should be paid to the therapeutic education of these patients being monitored for osteoporosis in order to optimise their management. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0193 30-DAY READMISSION IN PATIENTS WITH SEPTIC ARTHRITIS AND IDENTIFYING INDEPENDENT PREDICTORS ASSOCIATED WITH READMISSION: INSIGHTS FROM NATIONAL READMISSION DATABASE
Authors: S. Piplani, V. Jelic, V. R. Bejugam, S. Kong, S. R. Goguri, M. Sedaghati, D. Damania, B. Johnson, C. Tagoe
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Septic arthritis is a severe condition with notable morbidity and mortality. Limited knowledge exists regarding factors influencing the readmission of septic arthritis in real-world scenarios. <h3>Objectives:</h3> To explore 30-day readmission in patients with septic arthritis and identifying independent predictors associated with readmission using National Readmission Database (NRD). <h3>Methods:</h3> In this retrospective study, the 2019 data from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project Nationwide Readmission Database were utilized. The primary focus was on determining the rate of readmission for all causes within 30 days post-discharge. Secondary objectives included assessing hospital-level metrics such as length of stay, total hospitalization charges, and costs. The identification of independent risk factors for readmission was carried out through Cox regression analysis. <h3>Results:</h3> Of the 22,911 total index admissions, 851 resulted in readmissions. Males constituted the majority of index admissions at 64.8%, with a slightly higher readmission rate of 67.09%. The average age for index admissions was 58.1 years, decreasing to 54.1 years in readmitted patients. Insurance distribution showed a decline in readmissions among Medicare-insured patients (from 47.18% to 41.5%) and an increase among Medicaid-insured individuals (from 20.17% to 25.9%). Co-morbidities, such as chronic kidney disease (CKD), Hypertension, and Osteoarthritis, Alcohol Use, Liver Diseases, Thyroid Diseases, HIV, Other Connective Tissue disorders including RA, SLE, Sjogren's Syndrome were prevalent in both cohorts. On identifying most common diagnosis for Septic Arthritis readmissions, top prevalent were Pyogenic Arthritis (M00.9) and Staphylococcal Arthritis (M00.062). Total Length of Stay for all readmissions in the year 2019 was 6683.75 days with total charges of $57,100,000$ ± $4,881,148. Independent Predictors for Readmissions includes age ([aOR] 0.986, p&lt;0.0001), Medicaid insurance (aOR 1.46, p&lt;0.001), rehab transfer (aOR 3.39, p&lt;0.0001), smoking (aOR 1.46, p&lt;0.0001), and connective tissue combined disorders (aOR 0.73, p&lt;0.05). <h3>Conclusion:</h3> Septic arthritis imposes a significant strain on hospital outcomes due to recurrent readmissions, leading to substantial healthcare utilization in the year 2019 alone. It is crucial to carefully examine independent predictors of readmissions associated in regards to septic Arthritis. Although it was a limitation that only 2019 data was used, but still smoking was a risk factor for recurrent admissions and readmissions was least in patients who had highest income bracket. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0269 SLCO1B1 POLYMORPHISM IS NOT ASSOCIATED WITH ANTI-HMGCOAR IMMUNE-MEDIATED NECROTIZING MYOPATHY
Authors: C. Corrales-Selaya, D. Prieto-Peña, A. Corrales Martinez, C. Garcia-Ibarbia, Z. Salmón-García, M. Martín Millán, V. Portilla González, M. Sebastián Mora-Gil, J. Batista-Liz, V. Pulito Cueto, R. Lopez-Mejías, R. Blanco, J. L. Hernández Hernández
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy (IMNM) is a subgroup of idiopathic inflammatory myopathy that shows distinctive features from non-immune-mediated statin myotoxicity. A genomewide scan showed a strong association of statin myotoxicity with the rs4363657 single-nucleotide polymorphism (SNP) C allele within the <i>SLCO1B1</i> gene. However, it remains unknown if it is also associated with anti-HMGCGR-IMNM. <h3>Objectives:</h3> To determine whether Anti-HMGCR IMNM and non-immune-mediated statin myotoxicity exhibit a different <i>SLCO1B1</i> association. <h3>Methods:</h3> The rs4149056 (c.521T&gt;C) SNP within the SLCO1B1 gene was genotyped in 11 patients with anti-HMGCR IMNM diagnosis, 20 patients with non-immune- mediated statin myotoxicity and 31 ethnically matched controls receiving statins without myotoxicity. Comparisons were performed between the three groups. <h3>Results:</h3> Anti-HMGCR IMNM patients and non-immune-statin myotoxicity patients showed well-differentiated clinical features <b>(Table 1</b>). Anti-HMGCR were older, had more frequently hypertension and diabetes mellitus type2, were more commonly exposed to atorvastatine and showed more severe clinical symptoms and laboratory abnormalities. The prevalence of the rs4149056 C allele was 9.09%, 27.5% and 17.7% in anti-HMGCR IMNM, statin myotoxicity and controls, respectively. No statistically significant differences in the genotype and allele frequencies of <i>SLCO1B1</i> rs4149056 polymorphism were found when anti-HMGCR IMNM patients were compared to non-immune-statin myotoxicity patients and controls <b>(Table 2</b>). The prevalence of C allele and CC homozygotes was higher in patients with non-immune-statin myotoxicity when compared to anti-HMGCR IMNM and controls, but these differences were not statistically significant <b>(Table 2</b>). <h3>Conclusion:</h3> We found that <i>SLCO1B1</i> is not associated with an increased risk of anti-HMGCR IMNM. <h3>REFERENCES:</h3> <b>NIL.</b> <b>Table 1.</b> Demographic, clinical features and genetic distribution of SLCO1B1 rs4149056 in patients with anti-HMGCR IMNM, non-immune-mediated statin myotoxicity and patients taking statins without myotoxicity (controls). <b>Table 2.</b> Genetic differences of SLCO1B1 rs4149056 between patients with non-immune-mediated statin myotoxicity, patients with ant-HMGCR MNIM, and controls. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0232 MANAGING EARLY ARTHRITIS IN CLINICAL PRACTICE: STRUCTURED AND PROMPT INTERVENTION LEVERAGES WINDOW OF OPPORTUNITY AND LEADS TO EXCELLENT CLINICAL OUTCOMES
Authors: R. L. Teixeira, R. Vieira, J. Polido-Pereira, M. J. Saavedra, R. A. Moura, I. Alcobia, J. E. Fonseca, V. C Romão
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Inflammatory arthritides and other rheumatic diseases often present with clinical arthritis, leading to a significant personal and societal burden. Early arthritis clinics have been established worldwide to identify and treat patients within a window of opportunity, expecting to improve outcomes. <h3>Objectives:</h3> To describe the organization of our early arthritis clinic, which manages patients with untreated inflammatory arthritis with less than 12 months of symptoms. <h3>Methods:</h3> We included patients followed-up in our early arthritis clinic from 2015 to 2022. We collected demographic and clinical variables, including symptom duration, disease activity, treatment and final diagnosis. Patients were followed-up for up to 12 months, with visits at months 0, 1, 3, 6, 9 and 12. All patients were treated with short-term glucocorticoids and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with a treat-to-target approach. We herein report the proportion of patients achieving clinical remission, defined by Disease Activity Score 28-joints with 4 variables C-reactive protein (DAS-28-4V-CRP), at month 6 and 12 of follow-up. <h3>Results:</h3> We assessed 292 patients in our clinic between 2015 and 2022. Mean (SD) symptom duration at baseline was 57.8 (16.0) months, with a mean DAS28-CRP of 3.5 (1.0) (Table 1). Seropositive (40.1%) and seronegative (17.3%) rheumatoid arthritis were the most common diagnoses, followed by psoriatic arthritis (12.4%). Most patients were treated with prednisolone (88.1%) and methotrexate (75.3%), while a short number of patients received leflunomide (4.5%), sulfasalazine (9.4%) and hydroxychloroquine (12.9%). Health Assessment Questionnaire (HAQ) improvement was 1.5 ± 0.4 points. As a whole, 83.7% of the patients achieved remission (DAS28-CRP&lt;2.6) at 6 months and 92.1% of the patients at 12 months, with limited hand and feet structural progression (Table 2). <h3>Conclusion:</h3> Our early arthritis clinic allowed for the prompt orientation, diagnosis, and treatment of patients with recent onset arthropathies. This has resulted in a high percentage of patients reaching disease remission, in accordance with a window of opportunity for timely treatment and improved outcomes. Our work highlights the relevance of early arthritis clinics in tertiary rheumatology centers. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0239 THERMOGRAPHIC ASSESSMENT OF DIGITAL VASCULOPATHY IN IDIOPATHIC INFLAMMATORY MYOPATHIES
Authors: F. Bozan, M. J. Villar, G. Dinsdale, A. L. Herrick, H. Chinoy, M. Hughes
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous autoimmune rheumatic diseases divided in subtypes: dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), anti-synthetase syndrome (ASyS) and overlap myositis (OL). Nailfold capillaroscopy examines capillaries next to the nailbed using high-magnification optical imaging, whereas thermography uses an infrared camera to measure the temperature of the skin, which is representative of underlying blood flow (and larger vessel function). Both techniques are used in the assessment of patients with systemic sclerosis (SSc) which has a vasculopathic component to its pathogenesis, help to differentiate primary Raynaud's phenomenon (RP) from RP secondary to SSc, and can predict SSc disease severity. Nailfold capillaroscopy abnormalities have been described in IIMs, more frequently in DM and ASyS, suggesting an underlying vasculopathic pathogenesis akin to SSc. However thermographic assessment has not been specifically studied in IIMs. <h3>Objectives:</h3> We aimed to report thermography findings in patients with IIM and the relationship with structural abnormalities of the microvasculature. <h3>Methods:</h3> We retrospectively reviewed patients with a clinical diagnosis of IIM seen in a national tertiary referral service who also had been assessed by thermography and also nailfold capillaroscopy. <h3>Results:</h3> The study included 20 patients (80% female, mean ±SD age at diagnosis 50 ±16 years) with DM (50%), ASyS (35%), OL (5%) and unclear diagnosis (10%), where 15 patients had thermography performed. 11 of 15 had normal rewarming after cold challenge (distal dorsal difference [DDD] at 23°C normal) and 4 were abnormal. Considering the abnormal thermography patients, 3 of them had normal rewarming after heat challenge (DDD at 30°C normal). The majority had abnormal nailfold capillaroscopy (n=15) where the most frequent findings were enlarged capillaries and decreased density. Considering those with abnormal capillaroscopy, 10 also had thermography performed, where most exhibited normal rewarming after cold challenge. 5 of 18 had RP (2 missing data), most of them with abnormal nailfold capillaroscopy but normal rewarming after cold challenge. <h3>Conclusion:</h3> Most patients had normal thermography findings and microvascular structural alterations were not obviously correlated with functional abnormalities. RP was infrequent. Such findings differ from those reported in SSc and need to be studied further to clarify underlying vasculopathic pathogenesis and differences that may exist in different subtypes. The added role of thermography as a biomarker to aid diagnosis and management in this group of patients is yet to be defined. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>